[1]
|
Erba, H.P. (2010) Has There Been Progress in the Treatment of Older Patients with Acute Myeloid Leukemia? Best Practice & Research Clinical Haematology, 23, 495-501. http://dx.doi.org/10.1016/j.beha.2010.09.012
|
[2]
|
Stavropoulou, V., Brault, L. and Schwaller, J. (2010) Insights into Molecular Pathways for Targeted Therapeutics in Acute Leukemia. Swiss Medical Weekly, 140, w13068. http://dx.doi.org/10.4414/smw.2010.13068
|
[3]
|
Adams, V.R. and Leggas, M. (2007) Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors. Clinical Therapeutics, 29, 1338-1353. http://dx.doi.org/10.1016/j.clinthera.2007.07.022
|
[4]
|
O’Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich, M.C. and Cherrington, J.M. (2003) SU11248 Is a Novel FLT3 Tyrosine Kinase Inhibitor with Potent Activity in Vitro and in Vivo. Blood, 101, 3597-3605. http://dx.doi.org/10.1182/blood-2002-07-2307
|
[5]
|
O’Farrell, A.M., Foran, J.M., Fiedler, W., Serve, H., Paquette, R.L., Cooper, M.A., Yuen, H.A., Louie, S.G., Kim, H., Nicholas, S., Heinrich, M.C., Berdel, W.E., Bello, C., Jacobs, M., Scigalla, P., Manning, W.C., Kelsey, S. and Cherrington, J.M. (2003) An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 9, 5465-5476.
|
[6]
|
Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.M., Bello, C.L., Allred, R., Manning, W.C., Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E. and Hossfeld, D.K. (2005) A Phase 1 Study of SU11248 in the Treatment of Patients with Refractory or Resistant acute Myeloid Leukemia (AML) or Not Amenable to Conventional Therapy for the Disease. Blood, 105, 986-993. http://dx.doi.org/10.1182/blood-2004-05-1846
|
[7]
|
Yee, K.W., Schittenhelm, M., O’Farrell, A.M., Town, A.R., McGreevey, L., Bainbridge, T., Cherrington, J.M. and Heinrich, M.C. (2004) Synergistic Effect of SU11248 with Cytarabine or Daunorubicin on FLT3 ITD-Positive Leukemic Cells. Blood, 104, 4202-4209. http://dx.doi.org/10.1182/blood-2003-10-3381
|
[8]
|
Fiedler, W., Kayser, S., Kebenko, M., Janning, M., Krauter, J., Schittenhelm, M., Gotze, K., Weber, D., Gohring, G., Teleanu, V., Thol, F., Heuser, M., Dohner, K., Ganser, A., Dohner, H. and Schlenk, R.F. (2015) A Phase I/II Study of Sunitinib and Intensive Chemotherapy in Patients over 60 Years of Age with Acute Myeloid Leukaemia and Activating FLT3 Mutations. British Journal of Haematology, 169, 694-700. http://dx.doi.org/10.1111/bjh.13353
|
[9]
|
Ailles, L.E., Gerhard, B., Kawagoe, H. and Hogge, D.E. (1999) Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. Blood, 94, 1761-1772.
|
[10]
|
Mahadevan, D. and List, A.F. (2004) Targeting the Multidrug Resistance-1 Transporter in AML: Molecular Regulation and Therapeutic Strategies. Blood, 104, 1940-1951. http://dx.doi.org/10.1182/blood-2003-07-2490
|
[11]
|
Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., Dohner, H. and German-Austrian Acute Myeloid Leukemia Study Group (2008) Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. The New England Journal of Medicine, 358, 1909-1918. http://dx.doi.org/10.1056/NEJMoa074306
|
[12]
|
Mrozek, K., Marcucci, G., Paschka, P., Whitman, S.P. and Bloomfield, C.D. (2007) Clinical Relevance of Mutations and Gene-Expression Changes in Adult Acute Myeloid Leukemia with Normal Cytogenetics: Are We Ready for a Prognostically Prioritized Molecular Classification? Blood, 109, 431-448. http://dx.doi.org/10.1182/blood-2006-06-001149
|
[13]
|
Chou, T.-C. and Talalay, P. (1983) Analysis of Combined Drug Effects: A New Look at a Very Old Problem. Trends in Pharmacological Sciences, 4, 450-454. http://dx.doi.org/10.1016/0165-6147(83)90490-X
|
[14]
|
Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Lowenberg, B. and Reilly, J.T. (2003) Incidence and Prognosis of c-KIT and FLT3 Mutations in Core Binding Factor (CBF) Acute Myeloid Leukaemias. British Journal of Haematology, 121, 775-777. http://dx.doi.org/10.1046/j.1365-2141.2003.04362.x
|
[15]
|
Lamba, G., Gupta, R., Lee, B., Ambrale, S. and Liu, D. (2012) Current Management and Prognostic Features for Gastrointestinal Stromal Tumor (GIST). Experimental Hematology & Oncology, 1, 14. http://dx.doi.org/10.1186/2162-3619-1-14
|
[16]
|
Teng, C.L., Yu, C.T., Hwang, W.L., Tsai, J.R., Liu, H.C., Hwang, G.Y. and Hsu, S.L. (2013) Effector Mechanisms of Sunitinib-Induced G1 Cell Cycle Arrest, Differentiation, and Apoptosis in Human Acute Myeloid Leukaemia HL60 and KG-1 Cells. Annals of Hematology, 92, 301-313. http://dx.doi.org/10.1007/s00277-012-1627-7
|
[17]
|
Schnittger, S., Kohl, T.M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K. and Schoch, C. (2006) KIT-D816 Mutations in AML1-ETO-Positive AML Are Associated with Impaired Event-Free and Overall Survival. Blood, 107, 1791-1799. http://dx.doi.org/10.1182/blood-2005-04-1466
|
[18]
|
Geyer, S., Zhao, J., Caroll, A.J., Bucci, D., Vij, R., Blum, W., Pardee, T., Wetzler, M., Stock, W., Bloomfield, C.D., Larson, R.A. and Stone, R.M. (2013) Adding The KIT Inhibitor Dasatinib (DAS) to Standard Induction and Consolidation Therapy for Newly Diagnosed Patients (pts) with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results of the CALGB 10801 (Alliance) Study. Blood, 122, 357-357.
|
[19]
|
Kulke, M.H., Lenz, H.J., Meropol, N.J., Posey, J., Ryan, D.P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., Li, J.Z., Baum, C.M. and Fuchs, C.S. (2008) Activity of Sunitinib in Patients with Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 26, 3403-3410. http://dx.doi.org/10.1200/JCO.2007.15.9020
|
[20]
|
Cortes, J., Faderl, S., Estey, E., Kurzrock, R., Thomas, D., Beran, M., Garcia-Manero, G., Ferrajoli, A., Giles, F., Koller, C., O’Brien, S., Wright, J., Bai, S.A. and Kantarjian, H. (2005) Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients with Acute Leukemias and High-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 23, 2805-2812. http://dx.doi.org/10.1200/JCO.2007.15.9020
|
[21]
|
Cheng, F., Wang, L., Shen, Y., Xia, J., Chen, H., Jiang, Y. and Lu, M. (2016) Preclinical Evaluation of WYE-687, a mTOR Kinase Inhibitor, as a Potential Anti-Acute Myeloid Leukemia Agent. Biochemical and Biophysical Research Communications, 470, 324-330.
|
[22]
|
Hu, S., Niu, H., Minkin, P., Orwick, S., Shimada, A., Inaba, H., Dahl, G.V., Rubnitz, J. and Baker, S.D. (2008) Comparison of Antitumor Effects of Multitargeted Tyrosine Kinase Inhibitors in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 7, 1110-1120. http://dx.doi.org/10.1158/1535-7163.MCT-07-2218
|
[23]
|
Youle, R.J. and Strasser, A. (2008) The BCL-2 Protein Family: Opposing Activities That Mediate Cell Death. Nature Reviews Molecular Cell Biology, 9, 47-59. http://dx.doi.org/10.1038/nrm2308
|
[24]
|
Stander, B.A., Joubert, F., Tu, C., Sippel, K.H., McKenna, R. and Joubert, A.M. (2012) In Vitro Evaluation of ESE-15-ol, an Estradiol Analogue with Nanomolar Antimitotic and Carbonic Anhydrase Inhibitory Activity. PLoS ONE, 7, e52205. http://dx.doi.org/10.1371/journal.pone.0052205
|
[25]
|
Knapper, S., Mills, K.I., Gilkes, A.F., Austin, S.J., Walsh, V. and Burnett, A.K. (2006) The Effects of Lestaurtinib (CEP701) and PKC412 on Primary AML Blasts: The Induction of Cytotoxicity Varies with Dependence on FLT3 Signaling in both FLT3-Mutated and Wild-Type Cases. Blood, 108, 3494-3503. http://dx.doi.org/10.1182/blood-2006-04-015487
|
[26]
|
Patel, T., Gores, G.J. and Kaufmann, S.H. (1996) The Role of Proteases during Apoptosis. The FASEB Journal, 10, 587-597.
|
[27]
|
Gerber, J.M., Smith, B.D., Ngwang, B., Zhang, H., Vala, M.S., Morsberger, L., Galkin, S., Collector, M.I., Perkins, B., Levis, M.J., Griffin, C.A., Sharkis, S.J., Borowitz, M.J., Karp, J.E. and Jones, R.J. (2012) A Clinically Relevant Population of Leukemic CD34+CD38- Cells in Acute Myeloid Leukemia. Blood, 119, 3571-3577. http://dx.doi.org/10.1182/blood-2011-06-364182
|
[28]
|
Ran, D., Schubert, M., Taubert, I., Eckstein, V., Bellos, F., Jauch, A., Chen, H., Bruckner, T., Saffrich, R., Wuchter, P. and Ho, A.D. (2012) Heterogeneity of Leukemia Stem Cell Candidates at Diagnosis of Acute Myeloid Leukemia and Their Clinical Significance. Experimental Hematology, 40, 155-165.e1. http://dx.doi.org/10.1016/j.exphem.2011.10.005
|
[29]
|
Goussetis, E., Theodosaki, M., Paterakis, G., Peristeri, J., Petropoulos, D., Kitra, V., Papassarandis, C. and Graphakos, S. (2000) A Functional Hierarchy among the CD34+ Hematopoietic Cells Based on in Vitro Proliferative and Differentiative Potential of AC133+CD34Bright and AC133(dim/)-CD34+ Human Cord Blood Cells. Journal of Hematotherapy and Stem Cell Research, 9, 827-840. http://dx.doi.org/10.1089/152581600750062255
|
[30]
|
Horn, P.A., Tesch, H., Staib, P., Kube, D., Diehl, V. and Voliotis, D. (1999) Expression of AC133, a Novel Hematopoietic Precursor Antigen, on Acute Myeloid Leukemia Cells. Blood, 93, 1435-1437.
|